HighPoint Advisor Group LLC raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 13.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 229,367 shares of the biopharmaceutical company's stock after purchasing an additional 27,026 shares during the quarter. HighPoint Advisor Group LLC's holdings in Pfizer were worth $5,457,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Clarity Asset Management Inc. acquired a new stake in Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter worth about $28,000. Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the 4th quarter worth about $30,000. Finally, Horizon Financial Services LLC acquired a new position in shares of Pfizer during the 1st quarter worth about $35,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
Pfizer Stock Down 0.8%
PFE stock traded down $0.21 during trading on Monday, reaching $24.27. The stock had a trading volume of 33,436,955 shares, compared to its average volume of 41,926,715. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $137.96 billion, a P/E ratio of 7.62, a PEG ratio of 0.89 and a beta of 0.58. The firm has a fifty day moving average price of $24.07 and a 200 day moving average price of $24.71.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm's revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.82 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.09%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is presently 124.64%.
Analyst Ratings Changes
Several equities analysts have issued reports on PFE shares. Redburn Atlantic decreased their price objective on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Leerink Partners decreased their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. Citigroup increased their target price on shares of Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Berenberg Bank decreased their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Finally, BMO Capital Markets reduced their price objective on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and a consensus price target of $28.55.
Check Out Our Latest Stock Report on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
